Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Atebimetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuneering Reports Survival Data in Pancreatic Cancer at ASCO
    Immuneering Reports Survival Data in Pancreatic Cancer at ASCO

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3278411/0/en/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share
    Immuneering's AACR Data Backs Atebimetinib in Pancreatic Cancer
    Immuneering's AACR Data Backs Atebimetinib in Pancreatic Cancer

    20 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/20/3277094/0/en/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in-first-line-pancreatic-cancer-a.html

    GLOBENEWSWIRE
    20 Apr 2026
    Share Share
    Immuneering Presents Atebimetinib Data at 2026 AACR Meeting
    Immuneering Presents Atebimetinib Data at 2026 AACR Meeting

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257690/0/en/Immuneering-to-Present-Molecular-Data-at-2026-AACR-Annual-Meeting-from-Atebimetinib-Treated-Patients-Highlighting-Mechanism-Designed-to-Improve-Durability-and-Survival.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Immuneering Reveals 2025 Financials, Business Updates
    Immuneering Reveals 2025 Financials, Business Updates

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3250985/0/en/Immuneering-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Immuneering Touts 64% Survival, Fueling Race With Revolution
    Immuneering Touts 64% Survival, Fueling Race With Revolution

    08 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/immuneering-touts-64-1-year-survival-keeping-wheels-turning-race-revolution

    FIERCE BIOTECH
    08 Jan 2026
    Share Share
    Immuneering Reports 64% 12-Month Survival in Pancreatic Cancer
    Immuneering Reports 64% 12-Month Survival in Pancreatic Cancer

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214881/0/en/Immuneering-Announces-Exceptional-64-Overall-Survival-At-12-Months-in-First-Line-Pancreatic-Cancer-Patients-Treated-with-Atebimetinib-mGnP.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.